Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.

Trial Details

NCT ID
NCT07444814
Phase
PHASE1
Sponsor
Whitehawk Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • HWK-007
Locations (sample)
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Los Angeles, California, United States|34.05223,-118.24368
  • Peoria, Illinois, United States|40.69365,-89.58899
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

  • Have one of the following solid tumor cancers:
  • Monotherapy escalation and backfill cohorts:
  • non-squamous EGFR-Wt NSCLC
  • Endometrial carcinoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →